Ischemic stroke

Inhibiting ALOX15 by LX15002 provides long lasting protection against three key elements of ischemic stroke injury – brain edema, hemorrhage and neuronal cell death

Ischemic stroke occurs when a blood vessel in the brain is blocked, and the brain does not get the amount of blood it needs to function. It is the second leading cause of deaths globally and the leading cause of morbidity.

ALOX15 plays a driving force in 3 key mechanisms of Ischemic Stroke: Brain edema, hemorrhage and neuronal cell death. ALOX15 knockout mice are protected against neuronal injury and bleeding and specific inhibition of ALOX15 by LX15002 provides long lasting protection against stroke injury. With the help of a $6M BPN Neurotherapeutics Program grant, we have completed most of the IND enabling studies and planning for a biomarker driven, AI powered Phase 1 study

24h Infarct size reduction through LX15002:

Improvement after 4 weeks through 20 mg/kg LX15002:

The only approach target 3 key elements of ischemic stroke: brain edema, brain hemorrhage and neuronal cell death.
Completed most IND enabling studies with $6M non-dilutive funds.
Designed a biomarker enabled Phase 1a/b clinical trial powered by AI.